Irrespective of its binding partner, a low cytoplasmic level of UBE2N could be explained by the consequence of genomic instability (as a repair mechanism) and/or by the cause of the tumor to activate the NF-κB-associated progression of cancer. Here, UBE2N is linked to cancer.